We enable longer and healthier living through detection and monitoring of serious disease

At Chembio, our mission is to be a leader in the development, manufacture and commercialization of diagnostic solutions. We are dedicated to delivering exceptional products that provide ease of use, and rapid and accurate results at the point-of-care (POC). As a global company, we are committed to innovation and the highest quality standards.

At the core of our commitment is our patented Next Generation DPP® (Dual Path Platform) technology. Our DPP® technology is a breakthrough in POC diagnostics, offering significant advantages over lateral-flow technologies including:

Significantly improved sensitivity

Multiplexing – multiple test results via a single blood sample (e.g., HIV-Syphilis Assay)

Application in a number of indications

Today our DPP® technology is the basis of multiple collaborations with healthcare innovators and leaders worldwide spanning infectious diseases such as HIV, Zika, Ebola, syphilis, malaria and febrile illness, as well as potential new uses in the diagnosis of a specific form of cancer and brain injury (concussion).

Type
Public
HQ
Medford, US
Founded
1986
Size (employees)
131 (est)-15%
Chembio was founded in 1986 and is headquartered in Medford, US

Chembio Office Locations

Chembio has an office in Medford
Medford, US (HQ)
3661 Horseblock Road

Chembio Metrics

Chembio Financial Metrics

Revenue (2016)

$17.9 m

Revenue growth (2015-16), %

(26%)

Gross profit

$8.5 m

Gross profit margin (2016), %

47%

Net income (2016)

($13.3 m)

Market capitalization (21-Mar-2017)

$67.6 m

Closing share price (21-Mar-2017)

$5.5

Cash (31-Dec-2016)

$10.6 m
Chembio's current market capitalization is $67.6 m.
Chembio's revenue was reported to be $17.9 m in FY, 2016 which is a 26.3% decrease from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$29.5 m$27.6 m$24.3 m$17.9 m

Revenue growth, %

(6%)(12%)(26%)

Cost of goods sold

$17.2 m$16.8 m$13.8 m$9.4 m

Gross profit

$12.3 m$10.8 m$10.5 m$8.5 m

Gross profit Margin, %

42%39%43%47%

Operating expense total

$11.3 m$12.4 m$14 m$16 m

EBIT

$1 m($1.6 m)($3.6 m)($7.6 m)

EBIT margin, %

3%(6%)(15%)(42%)

Interest expense

$335$836

Interest income

$5.8 k$5.8 k$2.4 k$25.5 k

Pre tax profit

$1 m($1.6 m)($3.6 m)($7.5 m)

Income tax expense

$487 k($412.9 k)($1.2 m)$5.8 m

Net Income

$530.8 k($1.1 m)($2.4 m)($13.3 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$9.7 m$4.6 m$5.4 m$10.6 m

Accounts Receivable

Inventories

$3.2 m$3.6 m$3.6 m$3.3 m

Current Assets

$18.5 m$17.7 m$12.6 m$18.1 m

PP&E

$2 m$2.8 m$2.4 m$1.7 m

Total Assets

$24.5 m$25 m$20.8 m$20.6 m

Accounts Payable

Current Liabilities

$4.3 m$5.3 m$3.2 m$3.4 m

Additional Paid-in Capital

$46.9 m$47.6 m$47.9 m$60.7 m

Retained Earnings

($26.8 m)($27.9 m)($30.3 m)($43.7 m)

Total Equity

$20.2 m$19.7 m$17.7 m$17.2 m

Financial Leverage

1.2 x1.3 x1.2 x1.2 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

$530.8 k($1.1 m)($2.4 m)($13.3 m)

Depreciation and Amortization

$607.8 k$739.3 k$1.4 m$1.1 m

Accounts Receivable

$263.2 k($3.8 m)$5.9 m($960.8 k)

Inventories

($700.7 k)($449.6 k)$60.3 k$242.8 k

Accounts Payable

Cash From Operating Activities

$2.3 m($3.8 m)$1.8 m($6.7 m)

Cash From Investing Activities

($885.6 k)($1.5 m)($1 m)($668.7 k)

Interest Paid

($335)($836)

Chembio Operating Metrics

FY, 2016

Patents (US)

4

Products

3

Chembio Market Value History

Chembio Revenue Breakdown

Chembio Online Presence

Chembio Company Life

You may also be interested in